Frozen Section Tissue Staining For Non-Melanoma Skin Cancer in Mohs Micrographic Surgery

Irwan Saputra Batubara; Larisa Paramitha Wibawa; Adhimukti T Sampurna; Lis Surachmiati Suseno; Riesye Arisanty

doi:10.52830/inajcc.v3i1.65

Penulis

Irwan Saputra Batubara Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hosptial, Jakarta, Indonesia https://orcid.org/0000-0003-0210-7816 (tidak diautentikasi)
Larisa Paramitha Wibawa Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hosptial, Jakarta, Indonesia
Adhimukti T Sampurna Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hosptial, Jakarta, Indonesia
Lis Surachmiati Suseno Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hosptial, Jakarta, Indonesia
Riesye Arisanty Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo Hosptial, Jakarta, Indonesia

DOI:

https://doi.org/10.52830/inajcc.v3i1.65

Kata Kunci:

Mohs surgeryfrozen section, hematoxylin and eosin, basal cell carcinoma, squamous cell carcinoma.

Abstrak

Non-melanoma skin cancer has the highest incidence globally. The most common types of non-melanoma skin cancer are basal cell carcinoma and squamous cell carcinoma. Currently, Mohs micrographic surgery is the gold standard in the management of non-melanoma skin cancer because of its higher success rate, lower recurrence rate, and better cosmetic outcome compared to conventional surgery. Hematoxylin and eosin are commonly used for tissue staining of frozen sections in Mohs micrographic surgery. In some cases, other staining such as toluidine blue, hematoxylin and safranin O, periodic acid-Schiff, and oil red O are required to identify the characteristic features of various types of cancer. The use of properly frozen section tissue staining facilitates Mohs micrographic surgeon in determining the boundary of a cancer-free incision.